{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:03:35Z","timestamp":1784732615868,"version":"3.55.0"},"reference-count":32,"publisher":"Japanese Circulation Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2025,9,10]]},"DOI":"10.1253\/circrep.cr-25-0070","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T22:07:24Z","timestamp":1752271644000},"page":"826-831","source":"Crossref","is-referenced-by-count":1,"title":["Rationale and Design of the ESPIAL Trial\u3000\u2015 A Prospective, Randomized, Exploratory Study to Evaluate the Effect of Esaxerenone on Reduction of Urinary Albumin to Creatinine Ratio in Hypertensive Patients Concomitant With Heart Failure and Albuminuria \u2015"],"prefix":"10.1253","volume":"7","author":[{"given":"Shinichiro","family":"Suna","sequence":"first","affiliation":[{"name":"Department of Cardiovascular and Renal Medicine, Hyogo Medical University"},{"name":"Center for Clinical Research and Education, Hyogo Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Renal Medicine, Hyogo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Niki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka Ekisaikai Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Asanuma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Meiji University of Integrative Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Osaka Keisatsu Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Yasumura","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Amagasaki-Chuo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Kawarabayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tane General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kinki Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Okuhara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hakuhokai Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Hospital Organization Osaka Minami Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Goda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nishinomiya Watanabe Cardiovascular Cerebral Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, National Hospital Organization Osaka National Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kawasaki Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Okumura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Igeta","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Hyogo Medical University"},{"name":"Center for Clinical Research and Education, Hyogo Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Takagawa","sequence":"additional","affiliation":[{"name":"Center for Clinical Research and Education, Hyogo Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Asakura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Renal Medicine, Hyogo Medical University"},{"name":"Department of Clinical Diagnosis and Laboratory Medicine, Hyogo Medical University"},{"name":"Center for Clinical Research and Education, Hyogo Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Renal Medicine, Hyogo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>Eur Heart J<\/i> 2021; 42: 3599\u20133726.","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol<\/i> 2013; 62: e147\u2013e239.","DOI":"10.1161\/CIR.0b013e31829e8776"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>J Am Coll Cardiol<\/i> 2017; 70: 776\u2013803.","DOI":"10.1161\/CIR.0000000000000509"},{"key":"4","unstructured":"4. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol<\/i> 2022; 79: e263\u2013e421."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kitai T, Kohsaka S, Kato T, Kato E, Sato K, Teramoto K, et al. JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure. <i>Circ J<\/i> 2025; 89: 1278\u20131444.","DOI":"10.1253\/circj.CJ-25-0002"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Zhan R, Zhang J, Chen X, Liu T, He Y, Zhang S, et al. Targeting the efficacy of intensive blood pressure treatment in hypertensive patients: An exploratory analysis of SPRINT. <i>Circ J<\/i> 2023; 87: 1212\u20131218.","DOI":"10.1253\/circj.CJ-23-0037"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. <i>N Engl J Med<\/i> 1999; 341: 709\u2013717.","DOI":"10.1056\/NEJM199909023411001"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Selvaraj S, Claggett B, Shah SJ, Anand I, Rouleau JL, O\u2019Meara E, et al. Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction. <i>Circ Heart Fail<\/i> 2018; 11: e005288.","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. <i>N Engl J Med<\/i> 2011; 364: 11\u201321.","DOI":"10.1056\/NEJMoa1009492"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. <i>N Engl J Med<\/i> 2020; 383: 2219\u20132229.","DOI":"10.1056\/NEJMoa2025845"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. <i>N Engl J Med<\/i> 2021; 385: 2252\u20132263.","DOI":"10.1056\/NEJMoa2110956"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. de Boer RA, Nayor M, deFilippi CR, Enserro D, Bhambhani V, Kizer JR, et al. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction. <i>JAMA Cardiol<\/i> 2018; 3: 215\u2013224.","DOI":"10.1001\/jamacardio.2017.4987"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Fujimoto W, Odajima S, Okamoto H, Iwasaki M, Nagao M, Konishi A, et al. Importance of B-type natriuretic peptide in the detection of patients with structural heart disease in a primary care setting. <i>Circ J<\/i> 2024; 88: 732\u2013739.","DOI":"10.1253\/circj.CJ-23-0930"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Okamoto C, Tsukamoto O, Hasegawa T, Matsuoka K, Amaki M, Kanzaki H, et al. Relative B-type natriuretic peptide deficiency may exist in diastolic dysfunction in subclinical population. <i>Circ Rep<\/i> 2024; 6: 151\u2013160.","DOI":"10.1253\/circrep.CR-24-0026"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ohte N, Kikuchi S, Iwahashi N, Kinugasa Y, Dohi K, Takase H, et al. Prognostic value of B-type natriuretic peptide level in patients with heart failure with a higher left ventricular ejection fraction. <i>Circ Rep<\/i> 2025; 7: 191\u2013197.","DOI":"10.1253\/circrep.CR-24-0172"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Miyazaki S, Inaba S, Higashi H, Tamaki S, Nishimura K, Maruyama K, et al. Validation of N-terminal pro B-type natriuretic peptide threshold for early detection of pre-heart failure in a general Japanese population: Toon Health Study. <i>Circ J<\/i> 2025; 89: 966\u2013972.","DOI":"10.1253\/circj.CJ-24-0774"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Matsumoto Y, Orihara Y, Asakura M, Min KD, Okuhara Y, Azuma K, et al. Urine albumin-to-creatinine ratio on admission predicts early rehospitalization in patients with acute decompensated heart failure. <i>Heart Vessels<\/i> 2022; 37: 1184\u20131194.","DOI":"10.1007\/s00380-022-02025-y"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. <i>Eur J Pharmacol<\/i> 2015; 761: 226\u2013234.","DOI":"10.1016\/j.ejphar.2015.06.015"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Duggan S. Esaxerenone: First global approval. <i>Drugs<\/i> 2019; 79: 477\u2013481.","DOI":"10.1007\/s40265-019-01073-5"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). <i>Hypertension<\/i> 2020; 75: 51\u201358.","DOI":"10.1161\/HYPERTENSIONAHA.119.13569"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: A KDIGO controversies conference report. <i>Kidney Int<\/i> 2011; 80: 17\u201328.","DOI":"10.1038\/ki.2010.483"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Quinn CT, Saraf SL, Gordeuk VR, Fitzhugh CD, Creary SE, Bodas P, et al. Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial. <i>Am J Hematol<\/i> 2017; 92: E520\u2013E528.","DOI":"10.1002\/ajh.24810"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Fukutomi M, Hoshide S, Eguchi K, Watanabe T, Shimada K, Kario K. Differential effects of strict blood pressure lowering by losartan\/hydrochlorothiazide combination therapy and high-dose amlodipine monotherapy on microalbuminuria: The ALPHABET study. <i>J Am Soc Hypertens<\/i> 2012; 6: 73\u201382.","DOI":"10.1016\/j.jash.2011.09.004"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Hwang YC, Yoon KH, Cha BS, Lee KW, Jang HC, Min KW, et al. Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension: A randomized, open-label, active-controlled, superiority, parallel-group clinical trial. <i>Int J Clin Pract<\/i> 2017; 71: e12987.","DOI":"10.1111\/ijcp.12987"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Boorsma EM, Ter Maaten JM, Damman K, van Essen BJ, Zannad F, van Veldhuisen DJ, et al. Albuminuria as a marker of systemic congestion in patients with heart failure. <i>Eur Heart J<\/i> 2023; 44: 368\u2013380.","DOI":"10.1093\/eurheartj\/ehac528"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Khan MS, Shahid I, Anker SD, Fonarow GC, Fudim M, Hall ME, et al. Albuminuria and heart failure: JACC State-of-the-Art Review. <i>J Am Coll Cardiol<\/i> 2023; 81: 270\u2013282.","DOI":"10.1016\/j.jacc.2022.10.028"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Ujiro S, Fujimoto W, Takemoto M, Kuroda K, Yamashita S, Imanishi J, et al. Impact of cardiorenal anemia syndrome on the prognosis of patients with chronic heart failure in Japan: Insights from the KUNIUMI Registry Chronic Cohort. <i>Circ J<\/i> 2025; 89: 463\u2013469.","DOI":"10.1253\/circj.CJ-24-0957"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Kitai T, Maruyama S, Kuwahara K, Tamura K, Kinugawa K, Kashihara N. Establishing cross-specialty expert consensus on the optimal management of hyperkalemia in patients with heart failure and chronic kidney disease. <i>Circ J<\/i> 2025; 89: 470\u2013478.","DOI":"10.1253\/circj.CJ-24-0844"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Ozaki Y, Uemura Y, Tanaka A, Yamaguchi S, Okajima T, Mitsuda T, et al. Clinical impacts of urinary neutrophil gelatinase-associated lipocalin in patients with chronic kidney disease undergoing percutaneous coronary intervention. <i>Circ J<\/i> 2024; 88: 944\u2013950.","DOI":"10.1253\/circj.CJ-24-0060"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Ruilope LM, Ortiz A, Lucia A, Miranda B, Alvarez-Llamas G, Barderas MG, et al. Prevention of cardiorenal damage: Importance of albuminuria. <i>Eur Heart J<\/i> 2023; 44: 1112\u20131123.","DOI":"10.1093\/eurheartj\/ehac683"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. <i>Eur Heart J<\/i> 2021; 42: 152\u2013161.","DOI":"10.1093\/eurheartj\/ehaa736"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kitao T, Konishi E, Itoh N, Hirata A. Verification of the impact of changes in the severity classification of proteinuria on the prognosis of hypertensive patients following the initiation of esaxerenone. <i>Circ Rep<\/i> 2025; 7: 37\u201346.","DOI":"10.1253\/circrep.CR-24-0142"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/9\/7_CR-25-0070\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T03:49:46Z","timestamp":1757735386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/9\/7_CR-25-0070\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-25-0070","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"article-number":"CR-25-0070"}}